Year archive

Purple Biotech Ltd. — 2026 filings

All 40 regulatory filings released by Purple Biotech Ltd. (PPBT) in 2026, sourced directly from the official regulator.

40 Filings

2026 Period

2026 filings (40)

Filing	Released	Lang
Purple Biotech Reports First Quarter 2026 Financial Results and Business Highlights Earnings Release Q1 2026	2026-05-15	English
Purple Biotech Reports First Quarter 2026 Financial Results and Business Highlights Report Publication Announcement	2026-05-15	English
Purple Biotech Announces New Data from CAPTN-3 Platform Tri-specific IM1240 Regulatory Filings	2026-04-27	English
Purple Biotech Announces New Data from CAPTN-3 Platform Tri-specific IM1240 Report Publication Announcement	2026-04-27	English
“Purple Biotech Establishes Scientific Advisory Board to Support Development of CAPTN-3 Tri-Specific Antibody Platform Regulatory Filings	2026-04-23	English
“Purple Biotech Establishes Scientific Advisory Board to Support Development of CAPTN-3 Tri-Specific Antibody Platform Report Publication Announcement	2026-04-23	English
Other Report or Announcement Director's Dealing	2026-04-18	English
Other Report or Announcement Director's Dealing	2026-04-18	English
Form 3 - INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES - YAEL MARGOLIN Director's Dealing	2026-04-17	English
Form 3 - INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES - YAEL MARGOLIN Director's Dealing	2026-04-17	English
Form 3 - INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES - ERIC ROWINSKY Director's Dealing	2026-04-17	English
Form 3 - INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES - ERIC ROWINSKY Director's Dealing	2026-04-17	English
Form 3 - INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES - ROBERT GAGNON Director's Dealing	2026-04-17	English
Form 3 - INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES - ROBERT GAGNON Director's Dealing	2026-04-17	English
Form 3 - INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES - SHAI LANKRY Director's Dealing	2026-04-17	English
Form 3 - INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES - SHAI LANKRY Director's Dealing	2026-04-17	English
Form 3 - INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES - Gil Efron Director's Dealing	2026-04-17	English
Form 3 - INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES - Gil Efron Director's Dealing	2026-04-17	English
Form 3 - INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES -Agmon Ido Director's Dealing	2026-04-17	English
Form 3 - INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES -Agmon Ido Director's Dealing	2026-04-17	English
Form 3 - INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES -Suzana Nahum-Zilberberg Director's Dealing	2026-04-17	English
Form 3 - INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES -Suzana Nahum-Zilberberg Director's Dealing	2026-04-17	English
Form 3 - INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES -MICHAEL SCHICKLER Director's Dealing	2026-04-17	English
Form 3 - INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES -MICHAEL SCHICKLER Report Publication Announcement	2026-04-17	English
AI Collaboration with Converge Bio to Accelerate Development of its Next-Generation Tri-Specific Antibody Platform Regulatory Filings	2026-03-25	English
AI Collaboration with Converge Bio to Accelerate Development of its Next-Generation Tri-Specific Antibody Platform Regulatory Filings	2026-03-25	English
FORM 20-F-For the fiscal year ended December 31, 2025 Annual Report FY 2025	2026-03-19	English
FORM 20-F-For the fiscal year ended December 31, 2025 Report Publication Announcement	2026-03-19	English
CORPORATE PRESENATATION - MARCH 2026 Investor Presentation	2026-03-19	English
CORPORATE PRESENATATION - MARCH 2026 Report Publication Announcement FY 2026	2026-03-19	English
Purple Biotech Regains Compliance with Nasdaq Minimum Bid Price Requirement Regulatory Filings	2026-03-17	English
Purple Biotech Regains Compliance with Nasdaq Minimum Bid Price Requirement Report Publication Announcement	2026-03-17	English
Other Report or Announcement Board/Management Information	2026-03-13	English
Other Report or Announcement Report Publication Announcement	2026-03-13	English
Purple Biotech Reports Fourth Quarter and Full Year 2025 Financial Results Earnings Release Q4 2025	2026-03-13	English
Purple Biotech Reports Fourth Quarter and Full Year 2025 Financial Results Report Publication Announcement	2026-03-13	English
ADS Ratio Change from 200 to 2000 ordinary shares for one ADS, effective at the beginning of trading on or about March 2, 2026 Share Issue/Capital Change	2026-02-26	English
ADS Ratio Change from 200 to 2000 ordinary shares for one ADS, effective at the beginning of trading on or about March 2, 2026 Report Publication Announcement	2026-02-26	English
Other Report or Announcement Investor Presentation	2026-01-13	English
Other Report or Announcement Report Publication Announcement	2026-01-13	English

Filings by year

2026 40 filings
2025 100 filings
2024 101 filings
2023 81 filings
2022 48 filings
2021 82 filings
2020 164 filings
2019 119 filings
2018 71 filings
2017 123 filings
2016 142 filings